Faron
Edit

Faron

https://www.faron.com/
Last activity: 30.08.2024
Active
Categories: CareDevelopmentDrugGrowthLearnManagementMarketMedTechSoftware
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the Company's investigational intravenous interferon beta-1a is a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
Followers
235
Website visits
13.2K /mo.
Mentions
159
Location: Finland, Mainland Finland, Turku
Employees: 11-50
Total raised: $5.26M
Founded date: 2007

Investors 1

DateNameWebsite
13.03.2022IPF Partne...ipfpartner...

Funding Rounds 1

DateSeriesAmountInvestors
29.06.2022-$5.26M-

Mentions in press and media 159

DateTitleDescription
30.08.2024Grant of optionsGrant of options Fri, Aug 30, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Grant of options Company announcement, August 30, 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First Nort...
29.08.2024Faron Pharmaceuticals: A New Dawn in Cancer TreatmentFaron Pharmaceuticals Ltd. is making waves in the biopharmaceutical ocean. The company, based in Turku, Finland, is on a mission to tackle aggressive cancers with its innovative immunotherapy, bexmarilimab. Recent developments have position...
27.08.2024Faron 2024 Half-Year Financial ResultsFaron 2024 Half-Year Financial Results Tue, Aug 27, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Faron Reports Half-Year Financial Results, 1 January – 30 June 2024 Company Announcement, 27 August...
26.08.2024FDA Grants Fast Track Designation for BexmarilimabFDA Grants Fast Track Designation for Bexmarilimab Mon, Aug 26, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS Compa...
20.08.2024Notice of Half-Year Financial ResultsNotice of Half-Year Financial Results Tue, Aug 20, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Faron Pharmaceuticals Notice of Half-Year Financial Results Company Announcement, 20 August 2024 TUR...
13.08.2024Traumakine Research Collaboration and DoD GrantTraumakine Research Collaboration and DoD Grant Tue, Aug 13, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Faron Announces Traumakine Research Collaboration and DoD Grant Press release, 13 August 2...
13.08.2024Duquesne Receives New $1.5 Million Grant to Expand Transplantation ResearchPITTSBURGH, Aug. 13, 2024 /PRNewswire/ -- Duquesne University has received a new $1.5 million grant that will expand research into using nanoparticle technology to preserve human limbs for transplantation surgeries. The grant awarded to Dr....
08.08.2024Appointment of Chief Financial OfficerAppointment of Chief Financial Officer Thu, Aug 08, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Appointment of Chief Financial Officer Company announcement, 8 August 2024 at 2:00 a.m. EDT / 7:00 ...
07.08.2024The Rise of Battery Banks: A New Era in Electric Vehicle InfrastructureThe electric vehicle (EV) revolution is upon us. As cities grow greener and technology advances, the need for efficient energy solutions becomes paramount. Enter battery banks—a concept that promises to reshape the landscape of EV infrastru...
07.08.2024Grant of optionsGrant of options Wed, Aug 07, 2024 11:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Grant of options Company announcement, August 7, 2024 at 10.00 a.m. BST / 12:00 p.m. EEST TURKU, FINLAND - Faron Pharmace...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In